The chemokine system in allogeneic stem-cell transplantation: A possible therapeutic target?

Expert Review of Hematology

Volumn 4, Issue 5, 2011, Pages 563-576

  Melve, Guro Kristin ^a   Ersvær, Elisabeth ^a,b,c   Kittang, Astrid Olsnes ^a,b   Bruserud, Øystein ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c BERGEN UNIVERSITY COLLEGE   (Norway)

Author keywords

acute myeloid leukemia; allogeneic stem cell transplantation; graft versus host disease; graft versus leukemia effect; GVHD; GVL effect; peripheral blood stem cell mobilization; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 9; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CYTOKINE RELEASE; DISEASE COURSE; DOWN REGULATION; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; MULTIPLE MYELOMA; NERVE CELL; NONHUMAN; OSTEOBLAST; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

CHEMOKINES; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; RECEPTORS, CHEMOKINE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 80053184174     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.54     Document Type: Review

References (132)

1. Huang XJ. Current status of haploidentical stem cell transplantation for leukemia. J. Hematol. Oncol. 1, 27 (2008).
2. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant. 42(6), 365-377 (2008).
3. Huang XJ, Liu DH, Liu KY et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 38(4), 291-297 (2006).
4. Franzke A. The role of G-CSF in adaptive immunity. Cytokine Growth Factor Rev. 17(4), 235-244 (2006). (Pubitemid 44038619)
5. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98(10), 2900-2908 (2001).
6. Bruserud Ø, Kittang AO. The chemokine system in experimental and clinical hematology. Curr. Top. Microbiol. Immunol. 341, 3-12 (2010).
7. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud Ø. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr. Top. Microbiol. Immunol. 341, 149-172 (2010).
8. Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr. Top. Microbiol. Immunol. 341, 173-191 (2010).
9. Kittan NA, Hildebrandt GC. The chemokine system: a possible therapeutic target in acute graft versus host disease. Curr. Top. Microbiol. Immunol. 341, 97-120 (2010).
10. Engelhardt BG, Crowe JE Jr. Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. Curr. Top. Microbiol. Immunol. 341, 121-146 (2010).
11. Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 25(2), 211-217 (2011).
12. Semerad CL, Christopher MJ, Liu F et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 106(9), 3020-3027 (2005). (Pubitemid 41565894)
13. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111(2), 187-196 (2003). (Pubitemid 36105917)
14. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 114(7), 1331-1339 (2009).
15. Katayama Y, Battista M, Kao WM et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124(2), 407-421 (2006). (Pubitemid 43121987)
16. Christopherson KW 2nd, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101(12), 4680-4686 (2003). (Pubitemid 36857720)
17. Tayebi H, Kuttler F, Saas P et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp. Hematol. 29(4), 458-470 (2001). (Pubitemid 32297670)
18. Theilgaard-Monch K, Raaschou-Jensen K, Palm H et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 28(11), 1073-1082 (2001). (Pubitemid 34030656)
19. Rutella S, Bonanno G, Pierelli L et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-α. Eur. J. Immunol. 34(5), 1291-1302 (2004). (Pubitemid 39256008)
20. Rutella S, Pierelli L, Bonanno G et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 100(7), 2562-2571 (2002).
21. Franzke A, Piao W, Lauber J et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 102(2), 734-739 (2003). (Pubitemid 36842000)
22. Tanaka J, Mielcarek M, Torok-Storb B. Impaired induction of the CD28- responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 91(1), 347-352 (1998). (Pubitemid 28018764)
23. Toh HC, Sun L, Soe Y et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin. Immunol. 132(1), 83-92 (2009).
24. + regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. Stem. Cells Dev. 19(3), 333-340 (2010).
25. + NKT cells. J. Immunol. 173(8), 4960-4966 (2004). (Pubitemid 39387778)
26. Schlahsa L, Jaimes Y, Blasczyk R, Figueiredo C. Granulocyte-colony- stimulatory factor: a strong inhibitor of natural killer cell function. Transfusion 51(2), 293-305 (2010).
27. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-γ. Blood 95(1), 270-276 (2000). (Pubitemid 30017252)
28. Vuckovic S, Kim M, Khalil D et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 101(6), 2314-2317 (2003). (Pubitemid 36302075)
29. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95(8), 2484-2490 (2000). (Pubitemid 30210524)
30. Tayebi H, Lapierre V, Saas P et al. Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. Br. J. Haematol. 114(3), 698-700 (2001). (Pubitemid 32953653)
31. Sun LX, Ren HY, Shi YJ, Wang LH, Qiu ZX. Recombinant human granulocyte colony-stimulating factor significantly decreases the expression of CXCR3 and CCR6 on T cells and preferentially induces T helper cells to a T helper 17 phenotype in peripheral blood harvests. Biol. Blood. Marrow. Transplant. 15(7), 835-843 (2009).
32. Ageitos AG, Singh RK, Ino K et al. IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: monocyte inhibition. J. Immunother. 21(6), 409-417 (1998). (Pubitemid 28493711)
33. Tanaka J, Toubai T, Tsutsumi Y et al. Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 104(3), 768-774 (2004). (Pubitemid 38970571)
34. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 92(1), 215-222 (1998). (Pubitemid 28303195)
35. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89(5), 1629-1634 (1997). (Pubitemid 27097456)
36. Nawa Y, Teshima T, Sunami K et al. G-CSF reduces IFN-γ and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function. Bone Marrow Transplant. 25(10), 1035-1040 (2000). (Pubitemid 30303591)
37. Sloand EM, Kim S, Maciejewski JP et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95(7), 2269-2274 (2000). (Pubitemid 30167724)
38. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99(12), 4370-4378 (2002). (Pubitemid 34627203)
39. Robinet E, Lapierre V, Tayebi H, Kuentz M, Blaise D, Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfus. Apher. Sci. 29(1), 53-59 (2003). (Pubitemid 36870848)
40. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98(12), 3186-3191 (2001).
41. Akkok CA, Liseth K, Hervig T, Ryningen A, Bruserud Ø, Ersvaer E. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy 11(6), 749-760 (2009).
42. Akkok CA, Hervig T, Stamnesfet S et al. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy (In Press) (2011).
43. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85(1), 275-282 (1995).
44. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr. Opin. Hematol. 9(3), 190-198 (2002). (Pubitemid 34275964)
45. Devine SM, Brown RA, Mathews V et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant. 36(6), 531-538 (2005). (Pubitemid 43118148)
46. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant. 39(10), 577-588 (2007). (Pubitemid 46729051)
47. Olsnes AM, Ryningen A, Ersv'r E, Bruserud Ø. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. J. Interferon Cytokine Res. 28(5), 297-310 (2008). (Pubitemid 351725302)
48. Liseth K, Ersvaer E, Hervig T, Bruserud Ø. Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J. Biomed. Biotechnol. 2010, 692097 (2010).
49. Richard C, Baro J, Bello-Fernandez C et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant. 15(5), 721-726 (1995).
50. Gore SD, Donnenberg AD, Zehnbauer BA, Weng LJ, Burke PJ. Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery. Leukemia 8(3), 409-419 (1994). (Pubitemid 24096694)
51. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415 (1995).
52. Herbert KE, Prince HM, Ritchie DS, Seymour JF. The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin. Biol. Ther. 10(1), 113-125 (2010).
53. Ray P, Krishnamoorthy N, Ray A. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells: regulators of T cell differentiation. Cell Cycle 7(18), 2826-2832 (2008).
54. Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 22(3), 466-473 (2008). (Pubitemid 351386716)
55. Olsnes AM, Hatfield KJ, Bruserud Ø. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J. BUON 14(Suppl. 1), S131-S140 (2009).
56. Von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343(14), 1020-1034 (2000).
57. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11(8), 674-680 (2010).
58. Sells RE, Hwang ST. Paradoxical increase in skin inflammation in the absence of CCR4. J. Invest. Dermatol. 130(12), 2697-2699. (2010).
59. + T cells and implications for autoimmunity. J. Neuroimmune Pharmacol. 5(2), 198-209 (2010).
60. Acosta-Rodriguez EV, Rivino L, Geginat J et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8(6), 639-646 (2007). (Pubitemid 46785128)
61. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8(9), 950-957 (2007). (Pubitemid 47300009)
62. + T cell precursor. J. Exp. Med. 205(8), 1903-1916 (2008).
63. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur. J. Immunol. 40(12), 3312-3316 (2010).
64. Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 206(3), 525-534 (2009).
65. Maggi L, Santarlasci V, Capone M et al. CD161 is a marker of all human IL-17- producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 40(8), 2174-2181 (2010).
66. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40(7), 1830-1835 (2010).
67. Ersvaer E, Melve GK, Bruserud Ø. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunol. Immunother. (In Press) (2011).
68. Ramirez JM, Brembilla NC, Sorg O et al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur. J. Immunol. 40(9), 2450-2459 (2010).
69. + regulatory T cells inthe human immune system. Nat. Rev. Immunol. 10(7), 490-500 (2010).
70. + regulatory T cells. J. Immunol. 177(2), 840-851 (2006). (Pubitemid 44036584)
71. Mailloux AW, Young MR. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit. Rev. Immunol. 30(5), 435-447 (2010).
72. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 108(2), 426-431 (2006). (Pubitemid 44061338)
73. Zhang N, Schroppel B, Lal G et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 30(3), 458-469 (2009).
74. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64(22), 8451-8455 (2004). (Pubitemid 39491786)
75. Res PC, Piskin G, De Boer OJ et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5(11), e14108 (2010).
76. + effector and memory T cell generation. Nat. Immunol. 4(9), 835-842 (2003). (Pubitemid 37098653)
77. Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J. Immunol. 184(8), 4079-4086 (2010).
78. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 45(1), 1-11 (2010).
79. Ferrara JL, Krenger W. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus. Med. Rev. 12(1), 1-17 (1998).
80. Ferrara JLM. The cytokine storm of acute graft-versus-host disease. Haematol. Rev. 8, 27 (1994).
81. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol. Oncol. 21(4), 149-161 (2003). (Pubitemid 38146266)
82. Barron L, Dooms H, Hoyer KK et al. Cutting edge: mechanisms of IL-2- dependent maintenance of functional regulatory T cells. J. Immunol. 185(11), 6426-6430 (2010).
83. Foley JE, Jung U, Miera A et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J. Immunol. 175(9), 5732-5743 (2005). (Pubitemid 41508056)
84. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk. Lymphoma 38(3-4), 221-234 (2000). (Pubitemid 30303657)
85. Carvalho A, Cunha C, Di Ianni M et al. Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant. 45(11), 1645-1652 (2010).
86. Iclozan C, Yu Y, Liu C et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol. Blood Marrow Transplant. 16(2), 170-178 (2010).
87. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113(6), 1365-1374 (2009).
88. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110(10), 3804-3813 (2007). (Pubitemid 350159652)
89. Hill GR, Olver SD, Kuns RD et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116(5), 819-828 (2010).
90. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9(9), 1144-1150 (2003). (Pubitemid 37173698)
91. Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 115(9), 1669-1677 (2010).
92. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 127(4), 450-458 (2009).
93. Oo YH, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 34(1), 45-54 (2010).
94. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int. Immunol. 20(11), 1361-1368 (2008).
95. Hirota K, Yoshitomi H, Hashimoto M et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204(12), 2803-2812 (2007). (Pubitemid 350179551)
96. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 180(1), 214-221 (2008).
97. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 58(3), 875-887 (2008). (Pubitemid 351364887)
98. + regulatory T cells in the hematolymphoid system. Exp. Hematol. 34(8), 1033-1040 (2006). (Pubitemid 44080379)
99. Agace W. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol. Lett. 128(1), 21-23 (2010).
100. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 29(11), 514-522 (2008).
101. Devine SM, Vij R, Rettig M et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/ SDF-1 interaction. Blood 112(4), 990-998 (2008).
102. Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol. Blood Marrow Transplant. 16(12), 1629-1648 (2010).
103. Elfenbein GJ, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp. Hematol. 32(4), 327-339 (2004). (Pubitemid 38410908)
104. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl. Immunol. 17(3), 193-197 (2007).
105. Ringden O, Labopin M, Gorin NC et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 22(3), 416-423 (2004). (Pubitemid 41079769)
106. Khoury HJ, Loberiza FR Jr, Ringden O et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 107(4), 1712-1716 (2006). (Pubitemid 43242413)
107. Morris ES, Macdonald KP, Kuns RD et al. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat. Med. 15(4), 436-441 (2009).
108. Hatfield KJ, Reikvam H, Bruserud Ø. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr. Med. Chem. 17(36), 4448-4461 (2010).
109. Leposavic G, Pilipovic I, Radojevic K, Pesic V, Perisic M, Kosec D. Catecholamines as immunomodulators: a role for adrenoceptor-mediated mechanisms in fine tuning of T-cell development. Auton. Neurosci. 144(1-2), 1-12 (2008).
110. Scadden DT. The stem-cell niche as an entity of action. Nature 441(7097), 1075-1079 (2006). (Pubitemid 43990719)
111. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425(6960), 841-846 (2003). (Pubitemid 37351468)
112. Ballen KK, Shpall EJ, Avigan D et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol. Blood Marrow Transplant 13(7), 838-843 (2007). (Pubitemid 46902439)
113. Ersvaer E, Hatfield K, Reikvam H, Bruserud Ø. Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies. Bone Marrow Res. DOI: 10.1155/2011/570796 (2011) (Epub ahead of print).
114. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr. Cancer Drug Targets 5(4), 229-248 (2005). (Pubitemid 40910557)
115. Dimberg A. Chemokines in angiogenesis. Curr. Top. Microbiol. Immunol. 341, 59-80 (2010).
116. Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a Phase II study in patients with acute leukemia at high risk of relapse. J. Clin. Oncol. 23(15), 3447-3454 (2005).
117. Alshemmari S, Ameen R, Gaziev J. Haploidentical hematopoietic stem-cell transplantation in adults. Bone Marrow Res. DOI: 10.1155/2011/303487 (2011) (Epub ahead of print).
118. Kanda J, Chao NJ, Rizzieri DA. Haploidentical transplantation for leukemia. Curr. Oncol. Rep. 12(5), 292-301 (2010).
119. Mehta J, Singhal S, Gee AP et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 33(4), 389-396 (2004). (Pubitemid 38313087)
120. Mielke S, Mciver ZA, Shenoy A et al. Selectively T Cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol. Blood Marrow Transplant. DOI 10.1016/j. bbmt.2011.05.019 (2011) (Epub ahead of print).
121. Mielke S, Nunes R, Rezvani K et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402- based photodepletion technique. Blood 111(8), 4392-4402 (2008).
122. Stuehler C, Mielke S, Chatterjee M et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114(13), 2829-2836 (2009).
123. Montero A, Savani BN, Shenoy A et al. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol. Blood Marrow Transplant. 12(12), 1318-1325 (2006). (Pubitemid 44858265)
124. Ciceri F, Bonini C, Stanghellini MT et al. Infusion of suicide-γene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised Phase I-II study. Lancet Oncol. 10(5), 489-500 (2009).
125. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant. 6(5), 283-289 (1990).
126. Hamann W, Bruserud Ø, Patel S, Schmidt H, Ehninger G, Pawelec G. Cytotoxic and proliferative functions of T lymphocyte clones derived very shortly after allogeneic bone marrow transplantation. Bone Marrow Transplant. 8(2), 113-118 (1991).
127. + T-cell clones derived early after allogeneic bone marrow transplantation. Scand. J. Immunol. 38(1), 65-74 (1993). (Pubitemid 23196409)
128. Olsnes AM, Ersvaer E, Ryningen A, Bruserud Ø. Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology 13(6), 329-332 (2008).
129. Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr. Top. Microbiol. Immunol. 341, 37-58 (2010).
130. + NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/ HLA-class I interaction. Blood 114(19), 4108-4116 (2009).
131. Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat. Rev. 35(8), 653-661 (2009).
132. Bruserud Ø, Ryningen A, Olsnes AM et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92(3), 332-341 (2007). (Pubitemid 350143542)